Enochian gets license for inhaled treatment tech

By The Science Advisory Board staff writers

Enochian BioSciences has acquired a license for technology that can potentially treat and prevent all variants of the coronavirus as well as influenza.

Developed by Dr. Serhat Gumrukçu, PhD, director of Seraph Research Institute, the inhaled drug tricks the viruses to trigger the cells they infect to commit suicide instead of becoming virus-making factories. Delivered via a nanoparticle, the drug either rapidly treats an infection or waits for a cell to become infected before attacking it. It's possible a single inhalation of the drug could both treat and protect against infection for relatively long periods of time, according to Enochian.

The firm is requesting a preinvestigational new drug meeting with the U.S. Food and Drug Administration (FDA) soon.

Financial details of the license were not disclosed.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?